Skip Navigation


Glycobiology Advance Access originally published online on March 24, 2009
Glycobiology 2009 19(9):958-970; doi:10.1093/glycob/cwp038
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
19/9/958    most recent
cwp038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Perdivara, I.
Right arrow Articles by Przybylski, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perdivara, I.
Right arrow Articles by Przybylski, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Glycosylation profiles of epitope-specific anti-β-amyloid antibodies revealed by liquid chromatography–mass spectrometry

Irina Perdivara2,3, Leesa J Deterding3, Claudia Cozma2, Kenneth B Tomer3 and Michael Przybylski1,2

2 Department of Chemistry, Laboratory of Analytical Chemistry and Biopolymer Structure Analysis, University of Konstanz, 78457 Konstanz, Germany
3 Department of Health and Human Services, Laboratory of Structural Biology, Mass Spectrometry Group, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA


1 To whom correspondence should be addressed: Tel: +49-7531-882249; Fax: +49-7531-883097; e-mail: Michael.przybylski{at}uni-konstanz.de

Received on December 13, 2008; revised on March 1, 2009; accepted on March 9, 2009

Alzheimer's disease (AD) is the most prevalent form of age-related neurodementia. The accumulation of β-amyloid polypeptide (Aβ) in brain is generally believed to be a key event in AD. The recent discovery of physiological β-amyloid autoantibodies represents a promising perspective for treatment and early diagnosis of AD. The mechanisms by which natural β-amyloid autoantibodies prevent neurodegeneration are currently unknown. The aim of the present study was to analyze the N-linked glycosylation of a plaque-specific, monoclonal antibody (clone 6E10) relevant for immunotherapy of AD, in comparison with the glycosylation pattern of an Aβ autoantibody isolated from an IgG source. Liquid chromatography in combination with tandem mass spectrometry was used to analyze the glycopeptides generated by enzymatic degradation of the antibodies reduced and alkylated heavy chains. The oligosaccharide pattern of the 6E10 antibody shows primarily core-fucosylated biantennary complex structures and, to a low extent, tri- and tetragalactosyl glycoforms, with or without terminal sialic acids. The glycans associated with the serum anti-Aβ autoantibodies are of the complex, biantennary-type, fucosylated at the first N-acetyl glucosamine residue of the trimannosyl chitobiose core and contain zero to two galactose residues, and zero to one terminal sialic acid, with or without bisecting N-acetyl glucosamine. Glycosylation analysis of the Aβ-autoantibody performed at the peptide level revealed all four human IgG subclasses, with IgG1 and IgG2 as the dominant subclasses.

Key words: Aβ autoantibody / glycopeptides / glycosylation structures / immunoglobulin subclass / mass spectrometry


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.